Moolec Science S.A. (MLECW)

LU — Healthcare Sector
Peers: IBO  NRSN  VIVS  CYCN  TCRT  XTLB  CERO  AIM  YDES  BCLI 

Automate Your Wheel Strategy on MLECW

With Tiblio's Option Bot, you can configure your own wheel strategy including MLECW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MLECW
  • Rev/Share 1.617
  • Book/Share 1.0767
  • PB 15.2505
  • Debt/Equity 7.8974
  • CurrentRatio 1.478
  • ROIC -0.1515

 

  • MktCap 11922858.0
  • FreeCF/Share -0.9145
  • PFCF -5.0197
  • PE -9.8207
  • Debt/Assets 0.7038
  • DivYield 0
  • ROE -1.0231

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement
MLEC, MLECW
Published: January 22, 2026 by: Accesswire
Sentiment: Neutral

GEORGE TOWN, CAYMAN ISLANDS / ACCESS Newswire / January 22, 2026 / Moolec Science S.A. ("Moolec" or the "Company") today announced that it has received a decision from the Nasdaq Hearings Panel (the "Panel") granting the Company an exception through June 29, 2026 to demonstrate compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"), subject to certain disclosure conditions.

Read More
image for news Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement

About Moolec Science S.A. (MLECW)

  • IPO Date 2023-01-03
  • Website https://moolecscience.com
  • Industry Biotechnology
  • CEO Alejandro Antalich
  • Employees 52
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.